XTL Biopharmaceuticals Ltd. (XTLB)

NASDAQ: XTLB · IEX Real-Time Price · USD
2.790
+0.090 (3.33%)
Mar 28, 2024, 3:40 PM EDT - Market open
3.33%
Market Cap 14.78M
Revenue (ttm) n/a
Net Income (ttm) -1.35M
Shares Out 6.37M
EPS (ttm) -0.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 215,387
Open 2.640
Previous Close 2.700
Day's Range 2.560 - 2.830
52-Week Range 0.750 - 4.990
Beta 0.79
Analysts n/a
Price Target n/a
Earnings Date Nov 1, 2018

About XTLB

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 1, 2005
Employees 8
Stock Exchange NASDAQ
Ticker Symbol XTLB
Full Company Profile

Financial Performance

Financial Statements

News

XTL To Aquire The Social Proxy

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Place...

8 days ago - GlobeNewsWire

XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets co...

5 months ago - GlobeNewsWire

XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets co...

5 months ago - GlobeNewsWire